Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Focused on gene and cell therapies, this biotech innovator reported a notable insider sale amid a year of exceptional share price gains.
Overview
Harry Thomasian Jr. Chief Financial Officer of Precigen (NASDAQ:PGEN), reported the sale of 41,884 shares of common stock on May 28, 2026, as disclosed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 reported price ($4.36); post-transaction value based on May 28, 2026, market close ($4.36).
Details
* 1-year price change calculated using June 12, 2026, as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.